Evidence map›Paper›PMID 17581608›Full record

Trial reportLeukemia2007

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

R A Mesa, J K Camoriano, S M Geyer, W Wu, S H Kaufmann, C E Rivera, C Erlichman, J Wright, A Pardanani, T Lasho and 3 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.The Cochrane database of systematic reviews · 2015
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009
    Trial
  6. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
    Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Therapy of myelofibrosis (excluding JAK2 inhibitors).International journal of hematology · 2010
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

R A MesaDivision of Hematology, Rochester, MN, USA. mesa.ruben@mayo.edu
J K Camoriano
S M Geyer
W Wu
S H Kaufmann
C E Rivera
C Erlichman
J Wright
A Pardanani
T Lasho
C Finke
C Y Li
A Tefferi
University of Minnesota Rochester · USMayo Clinic · USJacksonville University · USMayo Clinic in Arizona · USNational Cancer Institute · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8288N01CM62205 · NCI · MAYO CLINIC ROCHESTER · PI ERLICHMAN, CHARLES · 2007 to 2011
$8.0M
NCI NIH HHS CA15083NCI NIH HHS N01CM62205
6 · The paper itself

Abstract

Patients with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) have limited therapeutic options. The farnesyltransferase-inhibitor tipifarnib inhibits in vitro proliferation of myeloid progenitors from such patients. In the current phase II clinical trial, single-agent oral tipifarnib (300 mg twice daily x 21 of 28 days) was given to 34 symptomatic patients with either PMF (n=28) or post-PV/ET MF (n=6). Median time to discontinuation of protocol therapy was 4.6 months; reasons for early termination (n=19; 56%) included disease progression (21%) and adverse drug effects (18%). Toxicities (>/=grade 3) included myelosuppression (n=16), neuropathy (n=2), fatigue (n=1), rash (n=1) and hyponatremia (n=1). Response rate was 33% for hepatosplenomegaly and 38% for transfusion-requiring anemia. No favorable changes occurred in bone marrow fibrosis, angiogenesis or cytogenetic status. Pre- and post-treatment patient sample analysis for in vitro myeloid colony growth revealed substantial reduction in the latter. Clinical response did not correlate with either degree of colony growth, measurable decrease in quantitative JAK2(V617F) levels or tipifarnib IC(50) values (median 11.8 nM) seen in pretreatment samples. The current study indicates both in vitro and in vivo tipifarnib activity in PMF and post-PV/ET MF.

Indexed as

AgedAged, 80 and overAnemiaAntineoplastic AgentsBone MarrowFemaleHumansJanus Kinase 2MaleMiddle AgedPolycythemia VeraPrimary MyelofibrosisProspective StudiesQuinolonesThrombocythemia, EssentialTreatment OutcomeAntineoplastic AgentsJAK2 protein, humanJanus Kinase 2Quinolonestipifarnib

Identifiers

PMID17581608
OpenAlexW2091165956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.